Aurinia Pharmaceuticals Inc (AUPH) Fundamentals

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States.
SHARE INFORMATION
Market Cap$ 1,651,289,407
Shares Outstanding128,225,927
Float141,319,158
Percent Float99.7%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 45,605,000
Latest Fiscal EPS$ -1.41
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions356
Institutional Holdings Date2022-04-30
Institutional Bought Previous 3 Months8,547,186
Institutional Holdings Percent44.4%
Institutional Sold Previous 3 Months14,285,160
Insider Holdings Date2022-03-31
Insider Bought Previous 3 Months1,192,858
Insider Holdings Percent0.3
Insider Sold Previous 3 Months100,801
Insider Shares Owned481,536
TRADING INFO
52 Week High$ 33.97
52 Week Low$ 8.86
52 Week High Change$ -9.13
21 Day Moving Average$ 10.7736
21 Day Extended Moving Average$ 10.991
50 Day Moving Average$ 11.3967
50 Day Extended Moving Average$ 11.8992
200 Day Moving Average$ 17.8897
200 Day Extended Moving Average$ 15.4101
10 Day Average Volume3,065,556
20 Day Average Volume2,466,814
30 Day Average Volume2,117,191
50 Day Average Volume2,123,277
Alpha0.018494
Beta1.0902
Standard Deviation0.261000
R20.039096
7 Day Price Change$ 1.76
7 Day Percent Change17.8%
21 Day Price Change$ 1.13
21 Day Percent Change10.74%
30 Day Price Change$ 0.50
30 Day Percent Change4.48%
Month to Date Price Change$ 1.36
Month to Date Percent Change13.22%
Quarter to Date Price Change$ -0.73
Quarter to Date Percent Change-5.9%
180 Day Price Change$ -16.82
180 Day Percent Change-59.08%
200 Day Price Change$ -21.43
200 Day Percent Change-64.78%
Year to Date Price Change$ -11.22
Year to Date Percent Change-49.06%

Aurinia Pharmaceuticals Inc (AUPH) Key Ratios

PROFITABILITY
EBIT Margin-253.4%
EBITDA Margin-248.6%
Pre-Tax Profit Margin-11,756.3%
Profit Margin Count0.0%
Gross Margin98.0%
Profit Margin TOT0.0%
INCOME STATEMENTS
Revenue$ 66,316,000
Revenue Per Share$ 0.4679
Revenue (3 Years)$ 467.55
Revenue (5 Years)$ 237.58
FINANCIAL STRENGTH
Price to Tangible Book3.60
Total Debt To Equity0.00
Int Coverage-1,458.70
Current Ratio14.10
Leverage Ratio1.20
Quick Ratio13.00
Long Term Debt To Capital0.02
VALUATION MEASURES
PE Ratio-8.80
Enterprise Value$ 1,178,742,111
Price to Sales24.9003
Price to Free Cash-10.50
PE High Last 5 Years-6.50
Price To Book3.60
Price To Cash Flow0.00
PE Low Last 5 Years-11.30
Price to Tangible Book3.60
MANAGEMENT EFFECTIVENESS
Receivables Turnover6.40
Invoice Turnover0.10
Assets Turnover0.10
Return Assets-37.35
Return on Equity-42.17
Return on Capital-40.34

Aurinia Pharmaceuticals Inc (AUPH) Profile

PROFILE INFO
Issue TypeCS
SEC TypeEQS
AuditorPricewaterhouseCoopers LLP
CEOPeter S. Greenleaf
Emplyoees300
Last AuditUQ
CIK0001600620
IndustryBiotechnology
SectorHealthcare
NAICSPharmaceutical Preparation Manufacturing(325412)
CONTACT INFO
Address4464 Markham Street
Suite 1203
Victoria, BC V8Z 7X8
Websitehttps://www.auriniapharma.com
Facsimile+1 604 369-4115
Telephone+1 250 708-4272
Emaildbourgeault@auriniapharma.com


Your Recent History
NASDAQ
AUPH
Aurinia Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.